AmpliPhi Biosciences Corporation 3579 Valley Centre Drive, Suite 100 San Diego, CA 92130 Press Release AmpliPhi Biosciences Reports Full-Year 2015 Financial Results San Diego

AmpliPhi Biosciences

Reports Full-Year 2015 Financial Results

March 30, 2016 - AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a global leader in developing bacteriophage-based

antibacterial therapies to treat drug-resistant infections, today announced its financial results for the fiscal year ended December

"AmpliPhi had a very productive 2015, making important

advances in our programs, raising capital to support development of our product candidates, and strengthening our management team

and Board of Directors," said M. Scott Salka, CEO of AmpliPhi Biosciences. "We have continued to make progress

into 2016, establishing our presence in San Diego, acquiring additional key bacteriophage assets and dosing the first patient in

our Phase 1 clinical trial of AB-SA01 for the treatment of Staphylococcus aureus infections in patients with chronic rhinosinusitis."

"Our achievements in 2015 and the anticipated

advancement of our pre-clinical and clinical pipeline in 2016 put us in a strong position to realize our vision of delivering innovative

phage-based therapies that address the serious and growing challenge of antibiotic-resistant bacterial infections," concluded

Fiscal Year-End 2015 Financial Results:

For more information, visit www.ampliphibio.com.

Conference Call Details

AmpliPhi Biosciences will host a conference call and webcast

to discuss its year-end 2015 financial results and provide an update on business activities. The event will be held today, March

30, 2016, at 4:30 p.m. Eastern Time (ET). The live event can be accessed through AmpliPhi's website at www.ampliphibio.com

under the Events and Presentations section, or by calling 800-895-0198 (domestic) or +1 785-424-1053 (international). The

conference ID is 9429197. A replay of the discussion will be available beginning at approximately 7:30 p.m. ET today on AmpliPhi's

website or by calling 888-203-1112 (domestic) or +1 719-457-0820 (international), using conference ID 9429197.

About AmpliPhi Biosciences

AmpliPhi Biosciences Corporation (NYSEMKT: APHB) is a biotechnology

company focused on the development and commercialization of novel bacteriophage-based antibacterial therapeutics. AmpliPhi's product

development programs target infections that are often resistant to existing antibiotic treatments. AmpliPhi is collaborating with

a number of leading organizations, including Intrexon Corporation (NYSE: XON), the U.S. Army, The Royal Brompton Hospital in London,

UK and UK-based University of Leicester, to advance bacteriophage-based therapies.

Bacteriophage are naturally occurring viruses that are highly

specific for the bacterial hosts they infect. They can rapidly kill their host, amplifying themselves in the process. Bacteriophage

are unaffected by antibiotic resistance and are able to disrupt bacterial biofilms. Such biofilms are a major line of defense for

bacteria, contributing to antibiotic resistance. Bacteriophage are able to penetrate biofilms and replicate locally to high levels,

to produce strong local therapeutic effects.

Forward Looking Statements

Statements in this press release that are not statements of

historical fact are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such

forward-looking statements include, without limitation, statements about the anticipated advancement

of AmpliPhi's pre-clinical and clinical pipelines in 2016, the potential use of bacteriophages to treat bacterial

infections, including infections that do not respond to antibiotics, and AmpliPhi's development of bacteriophage-based therapies.

Words such as "believe," "anticipate," "plan," "expect," "intend,"

"will," "may," "goal," "potential" and similar expressions are intended to identify

forward-looking statements, though not all forward-looking statements necessarily contain these identifying words. These forward-looking

statements are based upon AmpliPhi's current expectations and involve a number of risks and uncertainties, including the

risks and uncertainties described in AmpliPhi's Annual Report on Form 10-K for the year ended December 31, 2015, as filed

with the Securities and Exchange Commission. Actual results and the timing of events could differ materially from those anticipated

in such forward-looking statements as a result of these risks and uncertainties. You are cautioned not to place undue reliance

on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are

qualified in their entirety by this cautionary statement, and AmpliPhi undertakes no obligation to revise or update any forward-looking

statements to reflect events or circumstances after the date of this press release.